XORTX Announces Closing of US$1.1 Million Registered Direct Offering

Image for article XORTX Announces Closing of US$1.1 Million Registered Direct Offering
News Source : Financial Post

News Summary

  • XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease.
  • The gross proceeds from the Offering were US$1,102,500, before deducting placement agent fees and other offering expenses payable by the Company.
  • In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy.
  • At XORTX, we are dedicated to developing medications that improve the quality of life of individuals with important diseases.
CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ XRTX | TSXV XRTX | Frankfurt ANU), a latestage clinical pharmaceutical company focused on d [+5495 chars]

Must read Articles